High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma

Gynecologic Oncology

Volumn 133, Issue 2, 2014, Pages 197-204

  Stelloo, Ellen ^a   Nout, Remi A ^a   Naves, Lisanne C L M ^a   Ter Haar, Natalja T ^a   Creutzberg, Carien L ^a   Smit, Vincent T H B M ^a   Bosse, Tjalling ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Concordance; Curettage; Endometrial cancer; Hysterectomy; Microsatellite instability; Molecular alterations

Indexed keywords

BETA CATENIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CURETTAGE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION;

CONCORDANCE; CURETTAGE; ENDOMETRIAL CANCER; HYSTERECTOMY; MICROSATELLITE INSTABILITY; MOLECULAR ALTERATIONS;

AGED; AGED, 80 AND OVER; BETA CATENIN; BIOPSY; CARCINOMA, ENDOMETRIOID; CURETTAGE; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; GENETIC MARKERS; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PTEN PHOSPHOHYDROLASE; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899640423     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.02.012     Document Type: Article

References (36)

1. J.D. Wright, N.I. Barrena Medel, J. Sehouli, K. Fujiwara, and T.J. Herzog Contemporary management of endometrial cancer Lancet 379 2012 1352 1360
2. R.A. Nout, V.T. Smit, H. Putter, I.M. Jurgenliemk-Schulz, J.J. Jobsen, and L.C. Lutgens et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial Lancet 375 2010 816 823
3. H.M. Keys, J.A. Roberts, V.L. Brunetto, R.J. Zaino, N.M. Spirtos, and J.D. Bloss et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 744 751
4. C.L. Creutzberg, W.L. van Putten, P.C. Koper, M.L. Lybeert, J.J. Jobsen, and C.C. Warlam-Rodenhuis et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma Lancet 355 2000 1404 1411
5. Panici P. Benedetti, S. Basile, F. Maneschi, Lissoni A. Alberto, M. Signorelli, and G. Scambia et al. Systemic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial J Natl Cancer Inst 100 2008 1707 1716
6. H. Kitchener, A. Swart, Q. Qian, C. Amos, and M. Parmar Efficacy of systemic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study Lancet 373 2009 125 136
7. W.G. McCluggage, L. Hirschowitz, G.E. Wilson, E. Oliva, R.A. Soslow, and R.J. Zaino Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study Am J Surg Pathol 35 2011 289 294
8. A. Karateke, N. Tug, C. Cam, S. Selcuk, M.R. Asoglu, and S. Cakir Discrepancy of pre- and postoperative grades of patients with endometrial carcinoma Eur J Gynaecol Oncol 32 2011 283 285
9. X.Y. Wang, Z.M. Pan, X.D. Chen, W.G. Lu, and X. Xie Accuracy of tumor grade by preoperative curettage and associated clinicopathologic factors in clinical stage I endometriod adenocarcinoma Chin Med J (Engl) 122 2009 1843 1846
10. I.D. Mavromatis, C.N. Antonopoulos, I.L. Matsoukis, C.C. Frangos, A. Skalkidou, and G. Creatsas et al. Validity of intraoperative gross examination of myometrial invasion in patients with endometrial cancer: a meta-analysis Acta Obstet Gynecol Scand 91 2012 779 793
11. M.J. Zerbe, R. Bristow, F.C. Grumbine, and F.J. Montz Inability of preoperative computed tomography scans to accurately predict the extent of myometrial invasion and extracorporeal spread in endometrial cancer Gynecol Oncol 78 2000 67 70
12. S.K. Saarelainen, L. Koobi, R. Jarvenpaa, M. Laurila, and J.U. Maenpaa The preoperative assessment of deep myometrial invasion by three-dimensional ultrasound versus MRI in endometrial carcinoma Acta Obstet Gynecol Scand 91 2012 983 990
13. A. Akiyama-Abe, T. Minaguchi, Y. Nakamura, H. Michikami, A. Shikama, and S. Nakao et al. Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas Br J Cancer 109 2013 1703 1710
14. R.A. Nout, T. Bosse, C.L. Creutzberg, I.M. Jurgenliemk-Schulz, J.J. Jobsen, and L.C. Lutgens et al. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/beta-catenin and P53 pathway activation Gynecol Oncol 126 2012 466 473
15. I.B. Engelsen, I. Stefansson, L.A. Akslen, and H.B. Salvesen Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas Am J Obstet Gynecol 195 2006 979 986
16. L.C. Krol, N.A. 't Hart, N. Methorst, A.J. Knol, C. Prinsen, and J.E. Boers Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma Eur J Cancer 48 2012 1108 1115
17. S.W. Al, M. Salhab, V. Thomas, and K. Mokbel Is preoperative core biopsy accurate in determining the hormone receptor status in women with invasive breast cancer? Int Semin Surg Oncol 2 2005 15
18. S. Irshad, M. Bansal, M. Castillo-Martin, T. Zheng, A. Aytes, and S. Wenske et al. A molecular signature predictive of indolent prostate cancer Sci Transl Med 5 2013 202ra122
19. R. van Eijk, J. Licht, M. Schrumpf, Y.M. Talebian, D. Ruano, and G.I. Forte et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR PLoS One 6 2011 e17791
20. W.G. McCluggage, R.A. Soslow, and C.B. Gilks Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance Histopathology 59 2011 786 788
21. L.M. Seeber, R.P. Zweemer, L. Marchionni, L.F. Massuger, V.T. Smit, and W.M. van Baal et al. Methylation profiles of endometrioid and serous endometrial cancers Endocr Relat Cancer 17 2010 663 673
22. K. Garg, R.R. Broaddus, R.A. Soslow, D.L. Urbauer, D.A. Levine, and B. Djordjevic Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible Int J Gynecol Pathol 31 2012 48 56
23. R. van Eijk, L. Stevens, H. Morreau, and W.T. van Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis Exp Mol Pathol 94 2013 121 125
24. C.E. da Costa, K. Szuhai, E.R. van, M. Hoogeboom, R. Sciot, and F. Mertens et al. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies Genes Chromosomes Cancer 48 2009 239 249
25. A. Thanachaiviwat, C. Thirapakawong, C. Leelaphatanadit, and T. Chuangsuwanich Accuracy of preoperative curettage in determining tumor type and grade in endometrial cancer J Med Assoc Thai 94 2011 766 771
26. J. Mitchard, and L. Hirschowitz Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens Histopathology 42 2003 372 378
27. J.A. Francis, M.M. Weir, H.C. Ettler, F. Qiu, and J.S. Kwon Should preoperative pathology be used to select patients for surgical staging in endometrial cancer? Int J Gynecol Cancer 19 2009 380 384
28. I. Vandenput, J. Trovik, K. Leunen, E. Wik, I. Stefansson, and L. Akslen et al. Evolution in endometrial cancer: evidence from an immunohistochemical study Int J Gynecol Cancer 21 2011 316 322
29. S. Oreskovic, D. Babic, D. Kalafatic, D. Barisic, and L. Beketic-Oreskovic A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma Gynecol Oncol 93 2004 34 40
30. J. Trovik, E. Wik, I.M. Stefansson, J. Marcickiewicz, S. Tingulstad, and A.C. Staff et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer Clin Cancer Res 17 2011 3368 3377
31. G. Moreno-Bueno, D. Hardisson, C. Sanchez, D. Sarrio, R. Cassia, and G. Garcia-Rostan et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer Oncogene 21 2002 7981 7990
32. J.E. Fata, S. Debnath, E.C. Jenkins Jr., and M.V. Fournier Nongenomic mechanisms of PTEN regulation Int J Cell Biol 2012 2012 379685
33. J. Pallares, E. Bussaglia, J.L. Martinez-Guitarte, X. Dolcet, D. Llobet, and M. Rue et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities Mod Pathol 18 2005 719 727
34. C. Perez-Sanchez, E. Colas, S. Cabrera, O. Falcon, A. Sanchez-del-Rio, and E. Garcia et al. Molecular diagnosis of endometrial cancer from uterine aspirates Int J Cancer 133 2013 2383 2391
35. I. Kinde, C. Bettegowda, Y. Wang, J. Wu, N. Agrawal, and I. Shih et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers Sci Transl Med 5 2013 167ra4
36. J.M. Rhea, H.V. Singh, and R.J. Molinaro Next generation sequencing in the clinical molecular diagnosis of cancer Med Lab Obs 2011